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The abbreviations are: ATL, adult T-cell leukemia; HTLV-1, human T-cell lymphotropic 
virus type I; NF-κB, nuclear factor kappa B; XIAP, X-linked inhibitor of apoptosis 
protein. 
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Abstract 
Adult T cell leukemia/lymphoma (ATL) is a highly aggressive disease in which the 
human T-cell lymphotropic virus type I (HTLV-I) has been recognized as the etiologic 
agent. Fludarabine is a purine analogue that has demonstrated significant activity in 
B-cell malignancies, including chronic lymphocytic leukemia and indolent 
non-Hodgkin’s lymphoma. This study explored the effects of fludarabine on 
HTLV-1-infected T-cells (MT-1, -2, -4 and HUT102). Fludarabine induced growth arrest 
and apoptosis of these cells, as measured by 3-(4,5-dimethylithiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide assay, cell cycle analysis and annexin V staining. Moreover, 
exposure of HTLV-1-infected T cells to fludarabine decreased the levels of X-inhibitor 
of apoptosis protein in conjunction with inhibition of nuclear factor κB (NF-κB)/DNA 
binding activity, as measured by Western blot analysis and electrophoretic mobility shift 
and reporter gene assays, respectively. Further studies found that fludarabine 
accumulated NF-κB and inhibitory subunit of NF-κB in cytosole in conjunction with 
down-regulation of NF-κB in nucleus, suggesting that fludarabine blocked nuclear 
translocation of NF-κB. Taken together, fludarabine may be useful for treatment of 
individuals with ATL and other types of cancer in which NF-κB plays a role. 
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Introduction 
Adult T-cell leukaemia (ATL) is an aggressive malignancy of CD4+ T 
lymphocytes, in which the human T-cell lymphotropic virus type I (HTLV-I) has been 
recognized as the etiologic agent (1,2). Despite the development of intensive 
combination chemotherapy regimens supported by granulocyte colony-stimulating 
factor, median survival time of individuals with ATL is less than 13 months (3,4). Thus, 
it is urgent to develop new treatment strategies.  
Fludarabine is a purine analogue that has demonstrated significant activity in 
B-cell malignancies, including chronic lymphocytic leukemia and indolent 
non-Hodgkin’s lymphoma (5). Fludarabine is converted intracellularly into its active 
metabolite F-ara-ATP, which inhibits DNA as well as RNA synthesis, resulting in 
induction of growth arrest and apoptosis of tumor cells (6). Also, fludarabine has been 
included in conditioning regimens for stem cell transplantation because of its 
immnunosuppressive effect (7), although the mechanisms by which fludarabine inhibits 
T-cell function remain to be fully elucidated. 
Nuclear factor κB (NF-κB) is a transcription factor that regulates expression of 
various genes involved in cell cycle regulation and inhibition of apoptosis, such as 
cyclinD1 and Bcl-2 family members and X-linked inhibitor of apoptosis protein (XIAP) 
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as well as genes involved in inflammatory and immune responses (8-10). NF-κB acts as 
survival factors and is activated in various types of tumors including hematological 
malignancies (8-10). Previous studies found that NF-κB was activated in ATL cells and 
inhibitors of NF-κB such as PS11248, bortesomib, or oridonin effectively inhibited ATL 
cells (11-13).  
XIAP is a member of inhibitor of apoptosis proteins (IAPs), which selectively 
bind and inhibit caspases-3, -7, and -9, resulting in blockade of downstream portion of 
apoptosis pathway (14). XIAP is aberrantly expressed in variety types of solid tumor as 
well as leukemia cells and thought to be an attractive molecular target for cancer 
therapy (14).  
This study demonstrated new biological function of fludarabine; it 
downregulated levels of XIAP via inhibition of NF-κB in HTLV-1-infected T cells and 
induced growth arrest and apoptosis of these cells. 
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Materials and Methods 
Cell culture. HTLV-1-infected T-cell lines, MT-1, MT-2 and MT-4 were kind gifts of I. 
Miyoshi (Kochi Medical School, Kochi, Japan). HUT102 cells were generously 
provided by Y. Maeda (Kinki University School of Medicine, Osaka, Japan). Cells were 
suspended in standard RPMI 1640 medium (Sigma, St. Louis, Missouri) supplemented 
with 10% heat inactivated fetal bovine serum.   
Reagents. Fludarabine phosphate was provided by Schering AG (Berlin, Germany). 
MTT Assays. HTLV-1-infected cells (5x105/ml) were cultured with various 
concentrations of fludarabine for 2 days in 96-well plates (Flow Laboratories, Irvine, 
CA). After culture, cell number and viability were evaluated by measuring the 
mitochondrial-dependent conversion of the 3-(4,5-dimethylithiazol-2-yl)-2,5-diphenyl 
tetrazolium salt (MTT) (Sigma), to a colored formazan product. 
Immunoassays for the soluble form of CD30. The levels of soluble form of CD30 
(sCD30) in culture media were determined by a sandwich enzyme-linked 
immunosorbent assay (human sCD30 ELISA; Bender MedSystems, Vienna, Austria), as 
previously described (14). 
Cell Cycle analysis by Flow Cytometry. Cell cycle analysis was performed on 
HTLV-1-infected cells incubated with fludarabine (2.5 or 5 μM) for 2 days at 5x105 
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cells/ml in 12-well plates (Flow Laboratories, Irvine, CA). After incubation, cells were 
collected, fixed in chilled methanol and suspended in solution containing RNase A (100 
units/ml, Sigma) before staining with 50 μg/ml propidium iodide. A minimum of 10000 
cells were measured using FACSCalibur apparatus (Beckton Dickinson) and was 
analyzed using the CellQuest software package (Beckton Dickinson).  
Assessment of apoptosis. Cells were plated at a density of 1x105 cells/ml and incubated 
with fludarabine (2.5, 5 μM) for 2 days in 12-well plates (Flow Laboratories, Irvine, 
CA). The ability of fludarabine to induce apoptosis was measured by annexin V-FITC 
apoptosis detection kit according to the manufacturer’s instruction (Pharmingen, Inc., 
San Diego, CA). 
Electrophoretic Mobility Shift Assay (EMSA). Electrophoretic mobility shift assay 
(EMSA) was done as previously described (15). Briefly, 4 μg unclear extracts were 
incubated with 16 fmol 32P-end labeled, NF-κB binding probe. The DNA-protein 
complex was separated from the free oligonucleotide on a 5% polyacrylamide gel. Gels 
were dried and exposed to Kodak XAR film (Eastman Kodak, New Haven, CT).   
Transfections and Reporter Assay. Transfections and reporter assay was performed as 
previously described (13). Briefly, the NF-κB reporter construct (pGL3-NF-κB) 
containing three copies of NF-κB site cloned into pGL3-basic plasmid (Promega, 
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Meison, WI) was a generous gift form Dr. Moshe Arditi (Cedars-Sinai Medical Center, 
University of California at Los Angeles School of Medicine, Los Angeles, CA). MT-1 
cells cells (1x107) were transfected with pGL3-NF-κB (10 μg) by electroporation 
(150V). After 18 h, cells were exposed to fludarabine (2.5 μM) for 48 h. Luciferase 
activity in cell lysates was measured by the Dual Luciferase assay system (Promega, 
Madison, WI) which was normalized by Renilla activities.  
Western Blot Analysis. Western blot analysis was performed as described previously 
(13). Protein concentrations were quantitated using a Bio-Rad assay (Bio-Rad 
Laboratories, Hercules, CA). Proteins were resolved on a 10% SDS polyacrylamide gel, 
transferred to an immobilon polyvinylidene difluoride membrane (Amersham Corp., 
Arlington Heights, IL), and robed sequentially with antibodies. Anti-IκBα (Imgenex, 
San Diego, CA), anti-p65 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-XIAP (Cell 
Signaling Technology Inc., Beverly, MA), anti-Bcl-2 (Santa Cruz), anti-Bcl-xL (Santa 
Cruz) and anti-α-tubulin (Santa Cruz Biotechnology) antibodies were used.  
Immunocytochemistry. HUT102 cells were cultured either with or without fludarabine 
(5 μM). After 6 hrs, cells were harvested and cytocentrifuge slides were prepared. 
Anti-p65 (Santa Cruz) and anti-rabbit secondary antibodies (Amersham Corp.) were 
used for immunocytochemistry. Immune complexes were visualized using the LSAB2 
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system (Dako, Corp., Carpinteria, CA). Sections were counterstained with hematoxylin 
and mounted. 
Statistical analysis. All statistical analyses were carried out using the SPSS software 
(SPSS Japan, Tokyo, Japan) and the results were considered to be significant when the 
P-value was < 0.05. 
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Results 
Effect of fludarabine on proliferation of HTLV-1-infected T-cells.  
To examine the effects of fludarabine on the proliferation of HTLV-1-infected 
T-cells, we cultured MT-1, -2, -4 and HUT102 cells in the presence of various 
concentrations of fludarabine (0.1-5 μM) for 48 h. Their viability was determined by the 
MTT assay. Fludarabine inhibited the growth of MT-1, -4 and HUT102 cells with IC50 
ranging from 2.5 to 5 μM (Fig. 1A). The proliferation of MT-2 cells was also inhibited 
by fludarabine in a dose-dependent manner, although IC50 was not reached (Fig. 1A). 
We have recently shown that ATL cells produced soluble form of CD30 (sCD30) 
and serum levels of sCD30 correlated with disease activity (15). We therefore measured 
levels of sCD30 in culture media after exposure of HTLV-1-infected T-cells to 
fludarabine (Fig 1B). Control MT-1 cells produced 449 ± 55 U/ml sCD30 during 48 h 
culture; when these cells were exposed to fludarabine (2.5 or 5 μM), levels of sCD30 
decreased to 368 ±77 or 300 ± 43 U/ml, respectively (Fig. 1B). Levels of sCD30 in 
MT-4 and HUT102 were 94 ± 8 and 160 ± 6 U/ml, respectively. Exposure of these cells 
to fludarabine (2.5 μM, 48 h) significantly decreased levels of sCD30 by approximately 
70 or 50%, respectively (Fig. 1B).    
Effect of fludarabine on cell cycle distribution of HTLV-1-infected T-cells. 
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To investigate the mechanisms by which fludarabine inhibited the growth of 
HTLV-1-infected T-cells, we explored the effects of fludarabine on cell cycle 
distribution of these cells by flow cytometry (Fig. 2). Exposure of HTLV-1-infected 
T-cells to fludarabine (2.5 or 5 μM, 48h) prominently induced accumulation of these 
cells in the pre-G1 phase of the cell cycle, a feature characteristic of apoptosis with a 
concomitant decrease in the proportion of cells in the S phase (Fig. 2).   
Fludarabine induces apoptosis of HTLV-1-infected T-cells. 
To further confirm the ability of fludarabine to induce apoptosis of 
HTLV-1-infected T-cells, annexin V staining was utilized (Fig. 3). Annexin V binds to 
cells that express phosphatidylserine on the outer layer of the cell membrane, a 
characteristic in cells entering apoptosis. Exposure of HTLV-1-infected cells to 
fludarabine (2.5 μM, 48h) profoundly increased the population of cells positive for 
Annexin V (Fig. 3).  
Effect of fludarabine on levels of antiapoptotic proteins in HTLV-1-infected T-cells. 
We next examined whether fludarabine modulated the levels of antiapoptotic 
proteins, including XIAP, Mcl-1, Bcl-xl, and Bcl-2 by Western blot analysis. 
HTLV-1-infected T cells constitutively expressed XIAP, Mcl-1, and Bcl-xl proteins, 
which was consistent with the findings of previous studies (Fig. 4)(17). Exposure of 
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these cells to fludarabine (2.5 or 5 μM) for 48 h dramatically decreased levels of these 
proteins (Fig. 4). Likewise, HUT102 cells constitutively expressed Bcl-2 and exposure 
to fludarabine downregulated levels of Bcl-2 in these cells (Fig. 4). Levels of Bcl-2 
were not modulated in MT-4 cells after exposure to fludarabine (Fig. 4). Bcl-2 proteins 
were barely detectable in MT-1 and -2 cells; exposure of these cells to fludarabine (2.5 
or 5 μM) for 48 h induced levels of Bcl-2 (Fig. 4). 
Effect of fludarabine on NF-κB activity.  
The XIAP is one of the NF-κB target genes (14). We therefore examined whether 
fludrabine affected NF-κB activity in HTLV-1-infected cells (Fig. 5). We first utilized 
EMSA to explore the effect of fludarabine on NF-κB/DNA binding activity (Fig. 5A). 
Fludarabine (5 μM, 48 h) effectively disrupted the formation of NF-κB/DNA binding 
complex in MT-1, -2, and -4 cells (Fig. 5A). The NF-κB/DNA complex was tested in 
competition with a 100-times molar excess of unlabeled oligonucleotides, but not with 
the same molar excess of mutated oligonucleotides confirming the specificity of the 
NF-κB band (Fig. 5A). 
Moreover, we performed an NF-κB reporter assay to confirm the effect of 
fludarabine on NF-κB activity in HTLV-1-infected cells. We temporarily transfected 
MT-1 cells with an NF-κB reporter construct, and cultured these cells with either 
Nishioka, et al. 
 13
fludarabine or control diluent. MT-1 cells possessed measurable NF-κB transcriptional 
activity, and fludarabine (5 μM, 48 h) inhibited this activity by approximately 80% (Fig. 
5B). 
Activation of NF-κB involves two important steps: (i) phosphorylation and 
subsequent degradation of IκBα caused by IκB kinase resulting in the release of NF-κB, 
and (ii) the nuclear translocation of the activated NF-κB. To elucidate the effect of 
fludarabine on these steps, we measured the levels of NF-κB proteins in the cytoplasm 
and nucleus of HTLV-1-infected T-cells after exposure to fludarabine (Fig. 6). 
Fludarabine markedly decreased the levels of NF-κB in the nucleus, whereas the 
proteins accumulated in cytosol with the concomitant accumulation of IκBα in 
HTLV-1-infected cells, suggesting that fludarabine blocked the translocation of NF-κB 
from cytoplasm to nucleus (Fig. 6). Immunocytochemistry also showed that NF-κB 
accumulated in the nucleus in control HUT102 cells; however, exposure to fludarabine 
induced accumulation of NF-κB in cytoplasm (Fig. 6C), which further augmented our 
hypothesis that fludarabine inhibited nuclear translocation of NF-kB in 
HTLV-1-infected cells. 
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Discussion 
This study demonstrated a new biological action of fludarabine; it blocked 
NF-κB activity via inhibition of the degradation of IκBα and blockade of the nuclear 
translocation of NF-κB in HTLV-1-infected T-cells. In addition, we found that 
fludarabine downregulated the levels of NF-κB target protein including XIAP that 
functions as an anti-apoptotic molecule. This may be the molecular mechanism by 
which fludarabine induced apoptosis of HTLV-1-infected T-cells. Previous study has 
shown that the blockade of NF-κB by either diterpenoid oridonin (18), the proteasome 
inhibitor Velcade (Bortezomib) (19), or the IκB kinase inhibitor Bay 11-7082 (20) 
effectively induces apoptosis of ATL cells. Thus, NF-kB intimately involved in the 
regulation of pro-survival signals in ATL cells and can hence act as an attractive 
molecular target of treatment of this lethal disease.  
Fludarabine possesses potent activity in B-cell malignancies and is widely 
utilized for treatment of individuals with B-cell chronic lymphocytic leukemia (CLL) as 
a first line therapy (21). NF-κB is activated in CLL and new treatment strategy targeting 
this transcription factor has been undergoing testing in preclinical as well as clinical 
studies with favorable results; the proteasome inhibitor bortezomib which inhibits 
NF-κB showed biological activity in CLL cells (22-24). Fludarabine may inhibit the 
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growth of CLL cells at least in part via inhibition of NF-κB signaling.  
Recently, fludarabine was also shown to be effective for a subset of T-cell 
malignancies such as cutaneous T-cell lymphoma, although the number of patients was 
limited (25,26). This study for the first time demonstrated the efficacy of fludarbine in 
HTLV-1-infected T-cells in vitro. Larger clinical study is warranted to explore the effect 
of fludarabine against T-cell malignancies.      
Fludarabine possesses an immunosuppressive effect and is included in 
conditioning regimens for stem cell transplantation, although the precise mechanism 
whereby fludarabine suppresses immune functions remains unknown. Other 
investigators have found that fludarabine inhibits signal transducers and activator 
proteins 1 (STAT1) but not other STAT family members in peripheral blood 
mononuclear cells (PBMNCs) (27). Fludarabine inhibited the PHA-stimulated 
proliferation of PBMNCs and the production of interferon gamma (INF-γ) in these cells 
(27). The authors concluded that the immunosuppressive effect of fluarabine may be 
mediated by blockade of STAT1 (27). PHA is known to activate NF-κB in PBMNCs 
(28). Fludarabine probably blocks PHA-induced activation of NF-κB in PBMNCs, 
resulting in inhibition of production of inflammatory cytokines. This could also explain 
the immunosuppressive effects of fludarabine. Further studies will be required to 
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confirm our hypothesis. 
Taken together, fludarabine may be useful for the treatment of T-cell 
malignancies as well as inflammatory diseases such as graft versus host disease. 
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Figure legends 
Fig. 1. Inhibition of growth of HTLV-1-infected T-cells by fludarabine. (A), MTT 
assay. HTLV-1-infected T-cells (MT-1, -2, -4 and HUT102) were plated in 96-well 
plates and cultured with various concentrations of fludarabine (0.1-5 μM). After 48h, 
the cells were treated with MTT for 30min, and absorbance was measured. Results 
represent the mean±SD of 3 experiments performed in triplicate. (B), Immunoassay 
for sCD30. HTLV-1-infected T-cells (MT-1, -4 and HUT102) were plated in 6-well 
plates and cultured with fludarabine (2.5 or 5 μM) for 48 h. Cell culture supernatant 
was analyzed for levels of sCD30 by ELISA. Results represent the mean ± SD of three 
experiments with duplicate dishes per experimental point. Flu, fludarabine. 
Fig. 2. Cell cycle analysis. MT-1, -2, -4 and HUT102 cells were cultured with 
fludarabine (2.5 or 5 μM). After 48 h, cell cycle of these cells was analyzed. The 
statistical significance was determined by paired t-test. Results represent the mean ± SD 
of 3 experiments performed in duplicate. Flu, fludarabine. 
Fig. 3. Fludarabine increased the proportion of cells positive for Annexin V in 
HTLV-1-infected T-cells. MT-1, -2, -4 and HUT102 cells were cultured with 
fludarabine (2.5 μM). After 48h, cells were stained with annexin-V/ propidium iodide, 
and analyzed by flow cytometry. early apoptosis represents annexin-positive/propidium 
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iodide-negative cells; late apoptosis represents annexin-positive/propidium 
iodide-positive cells. 
Fig. 4. Effect of fludarabine on the expression of Bcl-2 family proteins. 
HTLV-1-infected MT-1, -2, -4, and HUT102 cells were treated with fludarabine (2.5 or 
5 μM) for 48h. The levels of Bcl-2 family proteins were determined by Western blot 
analysis. The membrane was sequentially probed with anti-XIAP, -Mcl-1, -Bcl-xl, Bcl-2, 
and -α-tubulin antibodies. 
Fig. 5. Effect of fludarabine on NF-κB activity in HTLV-1-infected T-cells. (A), 
EMSA. MT-1, -2, -4 and HUT102 cells were cultured either with or without fludarabine 
(2.5 or 5 μM). After 48 h, nuclear protein was extracted and subjected to EMSA. The 
arrow indicates the gel location of NF-κB bound to DNA. (B), NF-κB luciferase 
reporter assay. Shown at the top is the construct (pGL3-NF-κB) containing three 
copies of the NF-κB binding site cloned into pGL3-basic plasmid. MT-1 cells were 
transfected with pGL3-NF-κB. After 18 h, cells were exposed to fludarabine (2.5 μM, 
48 h). pRL-SV40-Luciferase (Renilla luciferase) vector was cotransfected for 
normalization. Results represent the mean ± SD of three experiments done in triplicate.   
Fig. 6. Fludarabine inhibited degradation of IκBα in cytosol and decreased levels 
of NF-κB in nucleus in HTLV-1-infected T-cells. MT-1, -2, -4 and HUT102 cells were 
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exposed to fludarabine (2.5 or 5 μM). After 48 h, cytoplasmic (A) and nuclear extracts 
(B) of these cells were prepared and subjected to Western blot analysis to measure the 
level of IκBα and p65 of NF-κB, respectively. Flu, fludarabine. (C), 
immunocytochemistry. HUT102 cells were cultured either with or without fludarabine 
(5 μM) for 6 hrs. Cells were harvested and cytocentrifuge slides were prepared. 
Anti-p65 and anti-rabbit secondary antibodies were used and immune complexes were 
visualized using the LSAB2 system. Sections were counterstained with hematoxylin. 
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